Orphan Drug Tax Credit – could you see it disappear?

congress orphan drugs tax credits (ron cogswell http://www.flickr.com/photos/22711505@N05/8395638981/)

We know that the Orphan Drug Tax Credit (ODTC) is a great incentive for orphan drug developers – but could you soon see it disappear? Shire, Vertex Pharmaceuticals,ViroPharma and BioMarin are reportedly among orphan drug firms urging Congress to maintain the ODTC amidst US tax reform proposals. The companies join the National Organization of Rare Disorders (NORD) and more than 70 patient organisations in voicing their concerns about the impact of dropping the ODTC.

Read more about this story at Total Orphan Drugs, our new blog promoting strategy and innovation in the rare disease industry >

Join our Orphan Drug discussion on LinkedIn, and sign up to our Total Orphan Drug newsletter

Leave a Reply

Your email address will not be published. Required fields are marked *